Navigation Links
UPDATE: FDA Approves New Drug to Treat Chronic Obstructive Pulmonary Disease
Date:3/1/2011

SILVER SPRING, Md., March 1, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration approved roflumilast, a pill taken daily to decrease the frequency of flare-ups (exacerbations) or worsening of symptoms from severe chronic obstructive pulmonary disease (COPD).

(Logo:  http://photos.prnewswire.com/prnh/20090824/FDALOGO)  

COPD is a serious lung disease that makes breathing difficult. Symptoms can include breathlessness, chronic cough, and excessive phlegm. An exacerbation can last up to several weeks and result in lung function decline, increased risk of death, and may be associated with severe anxiety.

Cigarette smoking is the leading cause of COPD, according to the National Heart, Lung, and Blood Institute. COPD is the fourth leading cause of death in the United States.

Roflumilast, a new drug class for the treatment of COPD, is an inhibitor of an enzyme called phosphodiesterase type 4 (PDE-4). It is indicated for people with severe COPD to treat the symptoms of cough and excess mucus linked to bronchitis. Roflumilast is not intended to treat another form of COPD which involves primary emphysema.

"COPD is a serious disease that gets worse over time," said Curtis Rosebraugh, M.D., M.P.H., director of the Office of Drug Evaluation II in the FDA's Center for Drug Evaluation and Research. "New treatment options that reduce frequency of flare-ups or exacerbations are important in helping patients with COPD associated with chronic bronchitis and a history of exacerbations in managing this debilitating disease."

The safety and effectiveness of roflumilast was demonstrated in two Phase 3 clinical studies that included more than 1,500 patients ages 40 and older who received roflumilast. Those treated had a history of COPD associated with chronic bronchitis and had experienced an exacerbation of the disease during the 12 months prior to beginning treatment.

The FDA approved roflumilast with a medication guide informing patients of the potential risks of mental health problems, including changes in mood, thinking, or behavior, as well as unexplained weight loss.

Roflumilast should not be used to treat sudden breathing problems (acute bronchospam), and is not recommended for people younger than 18 years. The most common side effects reported by those receiving roflumilast included diarrhea, nausea, headache, insomnia, back pain, decreased appetite, and dizziness.  

Roflumilast is marketed by St. Louis-based Forest Pharmaceuticals, a subsidiary of Forest Laboratories.

For more information:

National Heart, Lung, and Blood Institute: Chronic Obstructive Pulmonary Disease

Media Inquiries: Morgan Liscinsky, 301-796-0397, morgan.liscinsky@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA




'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. UPDATE: Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure
2. UPDATE: New Report by Pediatricians Finds Gaps in Preparing to Protect Kids From Pandemic Flu, Offers Recommendations
3. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. UPDATE: Infant Primates Given Vaccines on U.S. Childrens Immunization Schedule Develop Behavioral Symptoms of Autism
5. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
6. UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPars Investigational Cancer Drug BSI-201
7. UPDATE: FDA Issues 22 Warning Letters to Web site Operators
8. Update: International HIV/AIDS Partnership Wins Two Awards for Supply Chain Excellence
9. UPDATE: China PharmaHub Corp. Introduces a Magic Bullet Liver Cancer Therapy to China, Hong Kong, Taiwan, Macau, Singapore, Malaysia, and Bangladesh
10. Update: Clinical Trial Establishes Catheter-based Aortic Valve Replacement As New Standard of Care for Patients Who Cannot Undergo Surgery
11. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... After the recent election cycle, it ... cannabis both for medical and recreational purposes are shifting. The ... the use of cannabis, but the focus is coming from ... Research, the North American legal cannabis market posted $6.7 billion ... The research projects sales will grow at a compound annual ...
(Date:1/18/2017)... National Regulatory Authority Chinese Food and Drug Administration ... Flanders Institute Food and Drug Administration FORT ... Alliance Glaxo Smith Klein GlaxoWellcome ... Japan Immune Targeting Systems Indian ... of oxford Johnson & Johnson Krka Pharmaceuticals ...
(Date:1/17/2017)... , Jan. 17, 2017 Secretary of ... Alcohol Programs Secretary Gary Tennis are warning ... following two recent overdose deaths from the drug in ... "Carfentanil is intended to sedate large animals and is ... anyone who comes into contact with it," Secretary Murphy ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... In the ... Activewear is a stand-out company for several differences from other mainstream brands. ... on demand, this is called 'Agile' manufacturing - http://www.leanproduction.com/agile-manufacturing.html . It allows ...
(Date:1/17/2017)... ... 17, 2017 , ... Healthful Balance announces the national release ... operated by Ed Stroup, was created to offer the highest quality vitamins and ... customer service. Healthful Balance products can be purchased online through their website, or ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... enthusiasts at the National Association of Music Merchants (NAMM) winter trade show, Booth ... 2017. , Etymotic’s ER•4® has long been the gold standard for high-definition, in-ear ...
(Date:1/17/2017)... ... , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting provider , is ... Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted that Mirror Mirror ... Produced by Zeltiq, CoolSculpting is approved by the Food and Drug Administration as a ...
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons from New ... eye care practitioners on the latest breakthroughs in the prevention, diagnosis and treatment ... Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer of ...
Breaking Medicine News(10 mins):